Cardiff Oncology Current Ratio Growth & History (CRDF)

Cardiff Oncology's current ratio was 3.67 for fiscal 2025.

View full Cardiff Oncology company overview

Cardiff Oncology annual current ratio history

Cardiff Oncology annual current ratio

Fiscal yearPeriod endedCurrent ratioChangeGrowth
20252025-12-313.67−3.41−48.19%
20242024-12-317.08−0.34−4.53%
20232023-12-317.41−6.84−47.97%
20222022-12-3114.25−8.03−36.03%
20212021-12-3122.280.49+2.23%
20202020-12-3121.7919.42+817.87%
20192019-12-312.37−1.99−45.63%
20182018-12-314.371.97+81.97%
20172017-12-312.40−2.60−51.96%
20162016-12-315.00−3.34−40.09%
20152015-12-318.342.16+35.00%
20142014-12-316.18−6.80−52.41%
20132013-12-3112.98−2.15−14.21%
20122012-12-3115.1314.54+2468.31%
20112011-12-310.59

Cardiff Oncology current ratio trends

Over the last five fiscal years, Cardiff Oncology's current ratio decreased from 21.79 to 3.67, a change of −18.13. The latest reported quarter, Q2 2026, shows 3.30.

About the metric

What the current ratio means

The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.

Calculation and source

How the current ratio is calculated

TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Cardiff Oncology source filings ↗

Community posts

It’s quiet here.

No posts about CRDF yet. Start the conversation.

Write the first post